ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 801

Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1

Xuebing Feng1, Weiwei Chen2, Lihui Xiao1 and Lingyun Sun2, 1Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis, interferons, macrophage migration inhibitory factor (MIF) and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: While type I interferon
(IFN) has been linked to atherosclerosis progression in systemic lupus
erythematosus (SLE), little is known about its regulation and intervention. In this
study, we assessed the effect of IFN-alpha on several classic atherosclerosis
related factors, including macrophage migration inhibitory factor (MIF),
vascular endothelial growth factor (VEGF) and numbers of peripheral endothelial
progenitor cells (EPC), and explored the role of artesunate (ART), an
anti-malarial agent extracted from Chinese herbs, on this process.

Methods: Levels of MIF and VEGF in serum or
cultured supernatants were measured by ELISA, and numbers of peripheral EPC were
detected by flow cytometry. Their relationships with IFN scores that calculated
by 5 type I IFN gene (LY6E, OAS1, OASL, ISG15 and MX1) expression levels were
assessed by Spearman correlation analysis. ART at different concentrations was
added to human umbilical vein endothelial cells (HUVEC) cultures with or
without prior IFN- alpha 1b stimulation and to SLE peripheral blood mononuclear
cells (PBMC) cultures. To find out how ART regulated IFN signaling, the levels
of total and phosphorylated (p) STAT1, 3, 5 in cultured HUVECs were tested by
Western blot.

Results: Compared to age- and gender- matched
normal controls, SLE patients had lower EPC numbers, lower VEGF levels, but
higher MIF levels (all p < 0.0001). The reduction of EPC numbers and the increase of MIF levels were tightly correlated
with the elevation of IFN score in SLE patients (both p < 0.001). In
vitro
cultures showed that HUVEC produced significantly higher amount of
MIF after IFN-alpha stimulation, while VEGF levels varied at different time
periods by showing a decline after 12 hours stimulation but an increase at 24
hours. ART at 20 µmol/L significantly suppressed IFN-alpha promoted VEGF and
MIF production at 24 hours, along with the dramatic decline of IFN inducible
gene expressions. Similar to that in HUVEC, ART treatment also inhibited VEGF
and MIF production in SLE PBMC cultures. As shown in Figure 1, over-expression
of p-STAT1, but not p-STAT3 or 5, was detected after IFN-alpha stimulation,
which was completely reversed at the presence of ART.

Figure.tif

Conclusion: Our data supports a
potential role for type I IFN signaling in atherosclerosis. ART may
down-regulate IFN-alpha modulated pro-atherosclerotic factors through the
inhibition of STAT1 phosphorylation, thus could have therapeutic effect on
SLE-associated atherosclerosis.

 


Disclosure: X. Feng, None; W. Chen, None; L. Xiao, None; L. Sun, None.

To cite this abstract in AMA style:

Feng X, Chen W, Xiao L, Sun L. Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1 [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/artesunate-modulates-atherosclerosis-related-factors-through-the-inhibition-of-stat1/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/artesunate-modulates-atherosclerosis-related-factors-through-the-inhibition-of-stat1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology